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INTRODUCTION  
The term acute coronary syndrome refers to a range of 
acute myocardial ischaemic states. It encompasses 
unstable angina, non-ST segment elevation myocardial 
infarction (ST segment elevation generally absent), and 
ST segment elevation infarction (persistent ST segment 
elevation usually present).1 An acute coronary syndrome 
may occasionally occur in the absence of 
electrocardiographic changes or elevations in 
biochemical markers, when the diagnosis is supported by 
the presence of prior documented coronary artery disease 
or subsequent confirmatory investigations.
2
 In addition to 
primary prevention efforts, joint guidelines by the 
American College of Cardiology (ACC) and the 
American Heart Association (AHA) in 2007 suggest 
secondary drug prevention measures to be used in 
patients with ACS.3,4 In conjunction with diet and 
lifestyle modifications, these guidelines suggest the use 
of statins, beta-blocker, and renin-angiotensin 
aldosterone system inhibitor drug therapies in ACS 
patients.3,4 Several studies have shown survival benefit 
when these therapies were given to patients with ACS.  
Anti-platelet therapy (aspirin) is the single most cost-
effective adjunctive therapy for ACS treatment. It 
decreases mortality in treated patients by 23% (ISIS 2).5 
Multiple controlled trials have demonstrated that β-
blocker therapy use for ACS patients decreases both 
early and late cardiovascular mortality and re-infarction 
rate, and increases survival by 20 to 40%.6-10 The use of 
ACEI in treating ACS patients reduces mortality post-
myocardial infarction by 7% in ISIS-4 trial11 and by 12% 
in GISSI-3 trial.12 The use of lipid-lowering therapy 
(statin) in ACS patients has revealed decreased rate of 
progression and modest regression of atheromatous 
disease in treated patients. It reduces all-cause mortality 
by 45%.13 Several guidelines were established to 
improve care for ACS patients.14,15 These guidelines 
emphasizes the importance of using these 
pharmacotherapies in managing patients with ACS for 
secondary prevention. 
This study is aimed to show impact of drug utilization on 
quality of life of ACS patients, i.e., whether not using 
drugs from all these 5 groups in follow up patients of 
ACS due to contraindications or drug’s side effects 
would differently affect the quality of life of patients, as 
measured by “Minnesota living with heart disease 
questionnaire”16 as compared to the patients who 
received drugs from all 5 groups. 
MATERIALS AND METHODS 
The primary objective is to study the drug utilization 
pattern in post acute coronary syndrome patients in their 
follow up visits and secondary objective is to study how 
drug utilization pattern impacts health outcomes. 
Ethical considerations- 
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The study protocol, informed consent form (in Bengali, 
Hindi & English) and case report form (CRF) was 
submitted to the institutional ethics committee of 
R.G.Kar Medical College & Hospital, Kolkata for 
approval. Subject recruitment was commenced only after 
such approval is obtained.  
Written informed consents were taken from each 
participant according to standard accepted norms. 
Illiterate individuals gave their fingerprint (left thumb 
impression) instead of signature in the presence of an 
appropriate witness.  
Study duration- The study was completed within 18 
months after commencement. It ran from January 2011 
to June 2012. 
 Study population- Patients who have been recently 
suffered from acute coronary syndrome and are attending 
cardiology outdoor of R.G.Kar Medical College, 
Kolkata. 
Subject selection criteria-  
Inclusion criteria: Patient ( age group 20 yrs to 70 yrs) 
who have suffered acute coronary syndrome (unstable 
angina, ST elevation and non- ST Elevation acute 
myocardial infarction, diagnosed by ECG and/or 
biochemical tests) in recent past.  
Study methodology - 
It is a longitudinal prospective unicentric study done at 
the out patient department of cardiology and at the 
department of pharmacology, R.G.Kar Medical college, 
Kolkata.  
All prescriptions issued to study subjects attending the 
cardiology clinic during this whole study period were 
intercepted after consultation. Number of patients who 
received drugs from all  5 groups (aspirin, 
clopidogrel/prasugrel, beta blockers, ACE 
inhibitor/ARB, statin) were noted as well as patients who 
were not given drugs from all groups. Patients were 
asked 21 questions of “Minnesota living with heart 
disease questionnaire” and scores were calculated in 3 
visits of each patient. 1st visit was 1 week after discharge 
from hospital, subsequent visits were at 1 months and 3 
months following discharge.  
For health outcome at different visits, Kruskalwallis test 
was done to measure effectiveness of therapy of different 
groups (according to number of essential drug groups 
prescribed to different patients) and unpaired t test was 
done to evaluate whether quality of life score reduction 
differed significantly between these groups. 
RESULTS 
Total 525 patients were included in this study.  
Among them, 453 patients are male and 72 are female. 
Male: female ratio was 6.29:1.  
Majority of the patients were above 40 years of age with 
mean age 56.83 years and standard deviation 8.83 years. 
(table 1). 
 
Table 1: Demographic variables of study subjects 
Age of patients  Mean- 56.63 years, Standard deviation- 8.83  
Sex of patients  Male: female- 6.29:1  
Body mass index of patients  Mean- 22.12, Standard deviation- 2.06  
Monthly family income of patients  (in rupees)  Mean- 11628.57, Standard deviation- 6522.5  
Patients from Rural: urban background  1.10:1  
 
Among 525 patients, number of ST elevation acute 
myocardial infarction (ICD Code- I 21.0, 21.1, 21.2, 
21.3) were- 333(63.43%) , number of unstable angina 
patients (ICD Code- I 20.0)- 144 (27.43%), number of 
non ST elevation acute myocardial infarction ( ICD 
code- I 21.4) patients 48 (9.14%).  
Significant Co-morbidities: 
Total 135 patients out of 525 (25.71%) acute coronary 
syndrome patients had concomitant diabetes mellitus, 
290 patients (55.24%) had concomitant hypertension, 
103 patients (19.62%) had smoking history. Only 4 
patients (0.76%) had chronic kidney disease. 
Pattern of drug use: 
Antiplatelet agents: 
Aspirin was prescribed to all patients (100%). Among 
them 120 patients (22.86%) were given 75 mg aspirin 
per day, 402 patients (76.57%) were given 150 mg 
aspirin per day, 3 patients were given 300 mg aspirin per 
day. 
Clopidogrel was prescribed in 432 patients (82.29%). 
Among them 228 (52.78%) were given 75 mg/day and 
204 (47.22%) were given 150 mg/day. Prasugrel was 
given to 84 patients (16%) in 10 mg/day dose.it has been 
seen that 9 patients out of 525 (1.71%) were not given 
clopidogrel/ prasugrel. 
Beta blockers  
Beta blockers were prescribed in 456 patients (86.86%), 
among them, metoprolol was given in 384 patients 
(84.21%), carvedilol in 48 (10.53%) and atenolol in 24 
patients.(5.26%). ( Figure 1) 
Metoprolol was used in different dose from 12.5 mg/day 
to 100 mg/day. Most frequently (49.22%) prescribed 
dose of metoprolol was 50 mg/day.  
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Figure 1: Percentage of use of different beta blockers 
Angiotensin converting enzyme inhibitors(ACEI)/ 
angiotensin receptor blockers (ARB) 
Angiotensin converting enzyme inhibitors/ angiotensin 
receptor blockers were given in 459 patients (87.43%). 
Among them ramipril was given in 270 patients 
(58.62%), enalapril in 69 patients (15.03%), perindopril 
in 9 patients (1.96%), losartan in 57 patients (12.42%), 
telmisartan in 48 patients (10.46%), olmesartan in 6 
patients (1.31%). (figure 2). Among ramipril users, 120 
patients (44.44%) were given 2.5 mg/day and 123 
(45.56%) were given 5 mg/day dose. 6 patients received 
1.25 mg/day and 21 patients received 10 mg/day dose. 
 
 
 
Figure 2: Percentage of use of different ACE inhibitors/ARBs 
 
HMG-Co A reductase inhibitors  
Atorvastatin was given to 100% of patients and among 
them, 72 (13.71%) were given 20 mg/day dose, 276 
(52.57%) were given 40 mg/day dose and 177 (33.71%) 
were given 80 mg/day dose. 
Other drugs-  
Proton pump inhibitors in 411 patients (78.29%),  
Anxiolytics in 207 patients(39.43% ),  
Nitrates in 165 patients(31.43%),  
Calcium channel blockers in 93 patients (17.71%),  
Spironolactone in 90 patients (17.14%),  
Diuretics in 84 patients(16%, thiazide and loop 
diuretics),  
H2 receptor blockers in 84 patients (16%), 
 Cilostazole was used in 51 patients( 9.71%),  
Nicorandil was used in 36 patients (6.86%). 
For health outcomes, we measured the score of 
“Minnesota living with heart disease questionnaire” on 3 
visits of each study subjects, at the initial visit after 
discharge from hospital, 1 month after that and 3 months 
after that. There are 21 questions having score range 0 to 
5 for each question. Mean score at 1st visit,2nd and 3rd 
visit were 45.36, 24.29 and 12.94. Comparison between 
scores at different visits were done by Kruskalwallis test 
and Dunn’s multiple comparison test ( as post hoc test) 
and it showed very significant reduction in score 
(p<0.0001) while comparing between each two sets, i.e., 
between score at 1st visit and score after 1 month, 
between score at 1st visit and score after 3 months and 
between score after 1 month and score after 3 months. It 
indicates satisfactory improvement in quality of life due 
to drug therapy.  
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But there were some patients who were not given beta 
blockers (69 patients) nor ACE inhibitors/ Angiotensin 
receptor blockers (66 patients) or both due to some 
contraindications or adverse effects or other reasons. 
Total number of such patients was 117. Total 408 
patients were given all the drugs for main indication, i.e., 
aspirin-clopidogrel, beta blockers, statins, ACE 
inhibitors/ angiotensin receptor blockers. We compared 
scores of “Minnesota living with heart disease 
questionnaire” on 3 visits in these 2 groups by unpaired t 
test. (table 2)  
 
Table 2: evaluation of health outcome by improvement in quality of life 
visit Minnesota score in groups 
receiving 5 major drug groups 
Minnesota score in groups not 
receiving 5 major drug groups 
Test applied  P value 
1st Mean score- 47.18  
95% CI*- 45.22 to 49.14  
Mean score- 44.78  
95% CI- 43.56 to 46.00  
Unpaired t test.  0.0522 
2nd (after 1 month) Mean score- 29.23  
95% CI- 27.00 to 31.46  
Mean score- 22.57  
95% CI- 21.40 to 23.74  
Unpaired t test.  <0.0001 
3rd (after 3 months) Mean score- 16.95  
95% CI- 15.40 to 18.49  
Mean score- 11.86  
95% CI- 11.10 to 12.63  
Unpaired t test.  <0.0001 
*CI- Confidence interval 
This table showed that in patients who were given all the 
5 drugs for main indication fared significantly better than 
those who were not given all drugs. 
DISCUSSION 
From our study it is clear that incidence of ACS 
increases with age with a strong trend to peak over 60 
years. There is also a very high male:female ratio 
amongst ACS patients in this study, which is similar to 
other studies involving patients of acute coronary 
syndrome.17,18 
All the prescriptions were intercepted after consultation 
by a senior consultant cardiologist, thus reducing the 
impact of prescriber’s variables like age, sex, 
qualifications etc. on prescribing pattern.  
There was a high incidence of comorbid conditions like 
diabetes mellitus, hypertension and smoking among 
study subjects establishing their role in pathogenesis of 
ACS. 
The number of patients who were prescribed these drugs 
was high (87%) compared to similar other studies. The 
studies in Hyderabad, Saudi Arabia and Spain showed 
use of ACE inhibitors only in 45.71%, 59%, 32% 
respectively. A strong correlation was found regarding 
prescription of this group of drugs and presence of 
diabetes mellitus. 
Number of subjects prescribed beta blockers is quite 
satisfactory (86.86%) compared to other similar studies. 
The studies in Hyderabad19, Saudi Arabia20 and Spain21 
showed use of beta blockers in only 60%, 69% and 
50.2% patients respectively. 
And while comparing the score of “Minnesota living 
with heart disease questionnaire” on 3 visits of each 
study subjects, it has been found though there is overall 
significant satisfactory improvement with drug therapy. 
But while comparing the improvement over time 
between 2 groups (patients who were not prescribed 
drugs from all the 5 groups for main indication and 
patients who were given all the 5 drug groups), it was 
found that improvement over time is very significant in 
the latter group. It indicates that drugs from all these 5 
groups must be given to all follow up patients of ACS, 
unless contraindicated as they significantly improve 
quality of life of the patients with heart disease and this 
beneficial effect is additive with each drug group. 
CONCLUSIONS 
The quality of prescriptions among this important group 
of patients was very good compared to similar other 
studies, done in India or abroad.  
There is overall significant satisfactory improvement 
with drug therapy.  
Prescription of all 5 drug groups (as per AHA/ACC 2007 
guidelines) has significant better outcome in quality of 
life score than prescription of less than 5 drug groups.  
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